Kazia Therapeutics Annual Reports 2023

46 STATEMENT OF CASH FLOWS For the year ended 30 June 2023 Consolidated 2023 2022 restated Note $ $ Cash flows from operating activities Payments to suppliers (inclusive of GST) (15,179,270) (22,787,619) Interest received 23,113 Government grant - 10,000 Bad debt recovery - 14,956 Net cash used in operating activities 30 (15,156,157) (22,762,663) Cash flows from investing activities Payment of milestone relating to contingent consideration 18 - (2,364,732) Net cash used in investing activities - (2,364,732) Cash flows from financing activities Proceeds from issue of shares - net of issuance costs 20 12,971,997 3,726,187 Net cash from financing activities 12,971,997 3,726,187 Net decrease in cash and cash equivalents (2,184,160) (21,401,208) Cash and cash equivalents at the beginning of the financial year 7,361,112 27,586,760 Effects of exchange rate changes on cash and cash equivalents 64,245 1,175,560 Cash and cash equivalents at the end of the financial year 10 5,241,197 7,361,112 The above statement of cash flows should be read in conjunction with the accompanying notes FINANCIAL REPORT

RkJQdWJsaXNoZXIy MjE2NDg3